Skip to search formSkip to main contentSkip to account menu

carbovir triphosphate

Known as: CBV-TP 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Deoxyguanine Nucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Evaluation of Cerebral Hyperperfusion After Carotid Artery Stenting Using C‑Arm CT Measurements of Cerebral Blood Volume
PurposeHyperperfusion syndrome (HPS) after carotid artery stenting (CAS) causes serious symptoms; therefore, early evaluation… 
Review
2012
Review
2012
Feasibility of Cerebral Blood Volume Mapping by Flat Panel Detector CT in the Angiography Suite: First Experience in Patients with Acute Middle Cerebral Artery Occlusions
Because of the potential benefits of flat panel CT in assessing perfusion and the brain parenchyma, these investigators… 
2012
2012
Applicability of Tableside Flat Panel Detector CT Parenchymal Cerebral Blood Volume Measurement in Neurovascular Interventions: Preliminary Clinical Experience
BACKGROUND AND PURPOSE: CBV is a vital perfusion parameter in estimating the viability of brain parenchyma (eg, in cases of… 
2012
2012
Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects
Background Here, we aimed to investigate the pharmacokinetics of abacavir and carbovir triphosphate (CBV-TP) with darunavir… 
2010
2010
Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients
Objectives:To evaluate a potential pharmacodynamic/pharmacokinetic interaction between abacavir (ABC) and tenofovir disoproxil… 
Highly Cited
2009
Highly Cited
2009
Steady-State Pharmacokinetics of Abacavir in Plasma and Intracellular Carbovir Triphosphate following Administration of Abacavir at 600 Milligrams Once Daily and 300 Milligrams Twice Daily in Human…
ABSTRACT Abacavir (ABC) is administered either at 600 mg once daily (ABC 600 mg QD) or 300 mg twice daily (ABC 300 mg BID) in… 
2002
2002
Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate.
Abacavir (1592U89, or Ziagen) is a powerful and selective inhibitor of HIV-1 viral replication that has been approved by the FDA… 
Highly Cited
2001
Highly Cited
2001
Simultaneous determination of Ziagen and its phosphorylated metabolites by ion-pairing high-performance liquid chromatography-tandem mass spectrometry.
1999
1999
A Phase I Study of Abacavir (1592U89) Alone and in Combination With Other Antiretroviral Agents in Infants and Children With Human Immunodeficiency Virus Infection
Objectives. To evaluate the pharmacokinetic features, safety, and tolerance of abacavir, given alone and in combination with… 
1987
1987
Matching of Host Genotype and Serotypes of Coxsackie B Virus in the Development of Juvenile Diabetes
Thirty‐six consecutive paediatric patients (0‐16 years old) with recently contracted juvenile diabetes (IDDM) during 1982‐84 were… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)